These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16931453)

  • 1. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.
    Gorden P; Park JY
    Arch Physiol Biochem; 2006 Apr; 112(2):114-8. PubMed ID: 16931453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical uses of leptin.
    Gorden P; Gavrilova O
    Curr Opin Pharmacol; 2003 Dec; 3(6):655-9. PubMed ID: 14644019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical utility of leptin therapy in metabolic dysfunction.
    Park JY; Gavrilova O; Gorden P
    Minerva Endocrinol; 2006 Jun; 31(2):125-31. PubMed ID: 16682936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
    Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
    Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
    Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
    J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rethinking leptin and insulin action: therapeutic opportunities for diabetes.
    Yildiz BO; Haznedaroglu IC
    Int J Biochem Cell Biol; 2006; 38(5-6):820-30. PubMed ID: 16236542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency.
    McDuffie JR; Riggs PA; Calis KA; Freedman RJ; Oral EA; DePaoli AM; Yanovski JA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4258-63. PubMed ID: 15356018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin-replacement therapy for lipodystrophy.
    Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
    N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 20 years of leptin: leptin in common obesity and associated disorders of metabolism.
    DePaoli AM
    J Endocrinol; 2014 Oct; 223(1):T71-81. PubMed ID: 24973357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles.
    Fukaishi T; Minami I; Masuda S; Miyachi Y; Tsujimoto K; Izumiyama H; Hashimoto K; Yoshida M; Takahashi S; Kashimada K; Morio T; Kosaki K; Maezawa Y; Yokote K; Yoshimoto T; Yamada T
    Endocr J; 2020 Feb; 67(2):211-218. PubMed ID: 31708526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptin decreases de novo lipogenesis in patients with lipodystrophy.
    Baykal AP; Parks EJ; Shamburek R; Syed-Abdul MM; Chacko S; Cochran E; Startzell M; Gharib AM; Ouwerkerk R; Abd-Elmoniem KZ; Walter PJ; Walter M; Muniyappa R; Chung ST; Brown RJ
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin.
    Miyamoto L; Ebihara K; Kusakabe T; Aotani D; Yamamoto-Kataoka S; Sakai T; Aizawa-Abe M; Yamamoto Y; Fujikura J; Hayashi T; Hosoda K; Nakao K
    J Biol Chem; 2012 Nov; 287(48):40441-7. PubMed ID: 23024365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metreleptin treatment of non-HIV lipodystrophy syndromes.
    Chevalier B; Lemaitre M; Leguier L; Mapihan KL; Douillard C; Jannin A; Espiard S; Vantyghem MC
    Presse Med; 2021 Nov; 50(3):104070. PubMed ID: 34571177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.
    Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ
    F1000Res; 2019; 8():. PubMed ID: 31656583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.
    Rodríguez AJ; Neeman T; Giles AG; Mastronardi CA; Paz Filho G
    Arq Bras Endocrinol Metabol; 2014 Nov; 58(8):783-97. PubMed ID: 25465598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
    Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
    Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?
    Machado MV; Cortez-Pinto H
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):513-5. PubMed ID: 23985000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
    Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
    Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothalamic melanocortin signaling and leptin resistance--perspective of therapeutic application for obesity-diabetes syndrome.
    Masuzaki H; Tanaka T; Ebihara K; Hosoda K; Nakao K
    Peptides; 2009 Jul; 30(7):1383-6. PubMed ID: 19394382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.
    Bolze F; Bast A; Mocek S; Morath V; Yuan D; Rink N; Schlapschy M; Zimmermann A; Heikenwalder M; Skerra A; Klingenspor M
    Diabetologia; 2016 Sep; 59(9):2005-12. PubMed ID: 27272237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.